MEN.L

Molecular Energies
Molecular Energies - Issue of Equity
29th January 2024, 18:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2784B
Molecular Energies PLC
29 January 2024
 

A picture containing text, design, screenshot, graphics Description automatically generated

 

MOLECULAR ENERGIES PLC

("Molecular" or the "Company")

 

Issue of Equity

 

Molecular Energies (AIM: MEN), the international energy company, announces that, to satisfy payment of advisory services provided to the Company, it has allotted 160,000 new Ordinary Shares of 1 pence each in the Company ("Ordinary Shares").

 

Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 1 February 2024.

 

The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 12,378,197. The Company does not hold any shares in treasury. Accordingly, the figure of 12,378,197 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For more information, please visit www.molecularenergiesplc.com or contact:

 

Molecular Energies PLC

Peter Levine, Chairman

Rob Shepherd, Group FD

 

+44 (0)20 7016 7950

info@molecularenergiesplc.com

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

Simon Hicks, George Dollemore

 

+44 (0)20 7220 0500

Tavistock (Financial PR & IR)

Simon Hudson, Nick Elwes, Charles Baister

+44 (0)20 7920 3150

 

Notes to Editors

Molecular Energies PLC is an AIM listed company at the forefront of energy development and has interests across the energy spectrum, from an oil and gas project to the green and alternative energy sector.

 

The Company currently has an oil exploration asset in Paraguay. The Company has two separate subdivisions which are focused on early-stage opportunities in the green and/or alternative energy sub-sector.

 

Activities in the green and alternative energy space are being carried out direct through Molecular and under the Green House Capital brand and through AIM listed Atome Energy PLC, a green hydrogen, ammonia, and fertiliser company operating in Paraguay, Costa Rica and Iceland, in which Molecular currently has 20.5%.

 

With a strong strategic and institutional base of support, no third-party financial debt and a Chairman whose interests as the largest shareholder are aligned to those of its shareholders, Molecular gives UK investors access to an energy growth story combined with world class standards of corporate governance, environmental and social responsibility.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESEIFWUELSELF]]>
TwitterFacebookLinkedIn